Mitsubishi UFJ Financial Group Initiates Coverage on Charles River Laboratories (CRL)

Equities research analysts at Mitsubishi UFJ Financial Group began coverage on shares of Charles River Laboratories (NYSE:CRL) in a report issued on Friday. The firm set a “neutral” rating and a $115.00 price target on the medical research company’s stock. Mitsubishi UFJ Financial Group’s target price suggests a potential upside of 8.49% from the company’s previous close.

Several other equities analysts have also commented on CRL. Evercore ISI started coverage on shares of Charles River Laboratories in a research report on Thursday, January 18th. They set an “in-line” rating and a $117.00 price target for the company. SunTrust Banks lowered shares of Charles River Laboratories from a “buy” rating to a “hold” rating and upped their price target for the stock from $107.89 to $111.00 in a research report on Monday, January 22nd. They noted that the move was a valuation call. Robert W. Baird set a $123.00 price target on shares of Charles River Laboratories and gave the stock a “buy” rating in a research report on Tuesday, February 13th. JPMorgan Chase upped their price target on shares of Charles River Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Finally, Royal Bank of Canada set a $116.00 price objective on shares of Charles River Laboratories and gave the stock a “hold” rating in a report on Tuesday, February 13th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories currently has an average rating of “Buy” and a consensus price target of $116.71.

How to Become a New Pot Stock Millionaire

Charles River Laboratories stock opened at $106.00 on Friday. The stock has a market cap of $5,128.02, a PE ratio of 20.11, a PEG ratio of 1.62 and a beta of 0.68. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.54. Charles River Laboratories has a one year low of $86.66 and a one year high of $119.05.

Charles River Laboratories (NYSE:CRL) last released its quarterly earnings results on Tuesday, February 13th. The medical research company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.26 by $0.14. The business had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. Charles River Laboratories had a net margin of 6.64% and a return on equity of 26.14%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.21 earnings per share. equities research analysts predict that Charles River Laboratories will post 5.77 EPS for the current year.

In other Charles River Laboratories news, insider David Ross Smith sold 3,639 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $109.07, for a total value of $396,905.73. Following the completion of the sale, the insider now directly owns 15,110 shares of the company’s stock, valued at approximately $1,648,047.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Birgit Girshick sold 9,893 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $109.10, for a total transaction of $1,079,326.30. Following the completion of the sale, the insider now directly owns 26,470 shares of the company’s stock, valued at $2,887,877. The disclosure for this sale can be found here. Insiders sold a total of 62,658 shares of company stock valued at $6,875,393 over the last three months. 2.10% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Advisor Group Inc. lifted its holdings in Charles River Laboratories by 31.5% in the 4th quarter. Advisor Group Inc. now owns 2,023 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 485 shares during the last quarter. Amalgamated Bank raised its holdings in Charles River Laboratories by 5.5% during the 4th quarter. Amalgamated Bank now owns 9,905 shares of the medical research company’s stock worth $1,084,000 after buying an additional 514 shares during the period. Ladenburg Thalmann Financial Services Inc. raised its holdings in Charles River Laboratories by 69.0% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after buying an additional 548 shares during the period. Oakbrook Investments LLC raised its holdings in Charles River Laboratories by 14.6% during the 4th quarter. Oakbrook Investments LLC now owns 5,177 shares of the medical research company’s stock worth $567,000 after buying an additional 660 shares during the period. Finally, Aperio Group LLC raised its holdings in Charles River Laboratories by 3.0% during the 4th quarter. Aperio Group LLC now owns 25,612 shares of the medical research company’s stock worth $2,803,000 after buying an additional 739 shares during the period. 99.83% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Mitsubishi UFJ Financial Group Initiates Coverage on Charles River Laboratories (CRL)” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/04/20/mitsubishi-ufj-financial-group-initiates-coverage-on-charles-river-laboratories-crl.html.

Charles River Laboratories Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Analyst Recommendations for Charles River Laboratories (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply